Prepare interim, ongoing and other clinical study reports

How should interim and ongoing clinical study reports be presented?

State the data cutoff, study and follow-up status, analysis scope and relationship to earlier or future reports. Identify which conclusions remain provisional and how analyses were planned. Determine the appropriate M4E report family from the study’s purpose and design before assigning the residual other category.

Before you begin

Reports considered for 5.3.5.4, including interim or ongoing work and other clinical evidence not appropriately placed elsewhere. This is not a catch-all for incomplete filing decisions.

What you will prepare: An accurately classified report with an explicit evidence cutoff, appropriate depth and documented limitations.

Check the more specific report families first

M4E identifies several examples for 5.3.5.4, including interim analyses, ongoing studies and certain reports outside the claimed indication. Its neighboring instructions also place controlled safety studies and some studies supporting the indication in more specific locations. Determine the primary purpose, design and application role before choosing “other.”

Published clinical experience that is important to the efficacy demonstration may belong with the relevant efficacy evidence rather than being treated as background literature. Obtain the report, protocol or publication and the regulatory rationale. If relevance or access to underlying data is unknown, document the uncertainty and seek the owner's decision rather than hiding it under a broad label.

State what is mature and what is still changing

For interim or ongoing work, identify the data cutoff, enrollment/follow-up status, analysis scope and the relationship to any earlier or planned final report. Explain whether the analysis was prespecified, who had access to unblinded information where relevant and which conclusions remain provisional. Do not present a data snapshot as a completed study.

If proposing an abbreviated report, establish the appropriate depth for the study's role and the applicable regional advice. E3 permits flexibility; it does not make every discontinued, uncontrolled or nonpivotal study eligible for omission of important evidence. Describe the actual methods, available outcomes and material limitations so a reviewer can judge its contribution.

Keep updates from creating conflicting versions

Fictional exercise: an interim report uses an earlier cutoff than its newly prepared synopsis, but both are labeled with the same report version. Compare the data provenance, then align the package or explicitly identify the later analysis and its status. Do not silently replace only the synopsis while leaving the main report's evidence unchanged.

Maintain links between report versions and update the study listing to reflect the submitted material. If a later final report changes a preliminary conclusion, explain that relationship in the relevant report and summary. For a report available only as a publication, state the information limitations; do not reconstruct nonexistent participant-level results or pretend it is a full sponsor CSR.

Separate the study timeline from the report timeline

Use a version record whenever more than one snapshot contributes to the submission.

Update exercise: a newer table includes longer follow-up while the main narrative retains the earlier cutoff. Decide with the owners whether the table belongs to a new controlled analysis or is an erroneous replacement. Align the package and explicitly describe the relationship; changing the cover date alone cannot reconcile the evidence.

Update the clinical study listing and the synopses to describe exactly what is submitted. Preserve a material change in conclusion when a later report supersedes a preliminary interpretation.

Frequently asked questions

Sources and revisions

Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.

Related guides